Psyched: LSD For Major Depression, Canada's Large Scale Psilocybin Macrodose Trial, Treatments For Autism Spectrum Disorder And Multiple Sclerosis And More

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ:MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a t

BenzingaApr 24, 2023 15:58 ET

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC:NMLSF) has started recruiting participants for the first-ever clinical trial assessing

BenzingaApr 20, 2023 09:04 ET

Health Canada Grants Section 56 Exemption: Phase 2 Trial On Psilocybin For Leading Autism Cause

Wellbeing Digital (OTC:KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a g

Benzinga Real-time NewsFeb 14, 2023 13:37 ET

Nova Mentis Life Science Appoints Executive Chairman

Seeking AlphaJan 18, 2023 08:56 ET

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a

Benzinga Real-time NewsDec 27, 2022 12:48 ET

Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial

Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB:NMLSF) and Wellbeing Digital Sciences Inc. (OTC:KONEF)'s subsidiary KGK Sciences Inc. have submitted the first-ever Phase 2a Clinical Trial

Benzinga Real-time NewsNov 30, 2022 13:01 ET